1379401-24-7Relevant academic research and scientific papers
KINASE INHIBITORS
-
Paragraph 0414; 0415, (2016/12/12)
There are provided compounds of formula I. wherein R1 to R5, X1, X2, Ar, L, A, A1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
KINASE INHIBITORS
-
Paragraph 0308 - 0311, (2015/08/04)
There are provided compounds of formula (I), wherein R1 to R5, X1, X2, Ar, L, A, A1, E and G have meanings given in the description, which compounds have anti-inflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
KINASE INHIBITORS
-
Page/Page column 41; 43, (2014/03/25)
There are provided compounds of formula I, (I) wherein R1 to R5, X1, X2, Ar, L, E, A, A1, G and G1 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
KINASE INHIBITORS
-
Page/Page column 47, (2014/03/25)
There are provided compounds of formula (I), (Formula (I)) wherein R1 to R5, X1, X2, Ar, L, E, A, A1, G and G1 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
-
Paragraph 0084; 0085, (2013/04/23)
There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, in
1-PYRAZOLYL-3- (4- ( (2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- 1 - YL) UREAS AS P38 MAP KINASE INHIBITORS
-
Page/Page column 30, (2013/04/24)
There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
L-PYRAZOLYL-3- (4- ( (2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- 1 - YL) UREAS AS P3I MAP KINASE INHIBITORS
-
Page/Page column 20; 21, (2013/04/24)
There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
